Press release
Still's Disease Treatment Market Poised for Significant Growth, Driven by Therapies Targeting Novel Pathways | DelveInsight
Still's Disease - Market Insight, Epidemiology And Market Forecast - 2032
DelveInsight's "Still's Disease - Market Insight, Epidemiology And Market Forecast - 2032 [https://www.delveinsight.com/report-store/stills-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides comprehensive insights into Still's disease, including historical and forecasted epidemiology, current treatment approaches, and emerging therapies across the 7MM. The report presents a detailed understanding of the disease, historical and forecasted epidemiology, current treatment paradigms, emerging therapies, and market dynamics that will shape the Still's disease landscape over the next decade.
Still's disease, encompassing both adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA), is a rare autoinflammatory disorder characterized by persistent fever, typical salmon-colored rash, joint pain, and systemic inflammation. Recent research suggests these conditions may be part of a continuum of the same disease, prompting clinicians to seek unified approaches to diagnosis and management.
According to DelveInsight's latest market analysis, the Still's disease market is projected to expand significantly by 2032. The US leads the market, followed by EU4 and the UK, due to better healthcare infrastructure and higher awareness.
Download the Still's disease Market Forecast Report to understand which factors are driving the Still's disease therapeutic market @ Still's disease Market Trends [https://www.delveinsight.com/sample-request/stills-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Still's disease epidemiological studies show that the total diagnosed prevalent cases of AOSD were approximately 2.5K in the US in 2023. Among the EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases of AOSD, followed by France and the UK. Furthermore, the condition exhibits a bimodal age distribution, typically affecting individuals between 15-25 years and 36-46 years of age, with some studies indicating a higher prevalence among females.
Discover evolving trends in the Still's disease patient pool forecasts @ Still's disease Epidemiology Analysis [https://www.delveinsight.com/sample-request/stills-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The current treatment landscape for Still's disease involves a stepwise approach, beginning with first-line therapies consisting of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs), followed by second-line options including methotrexate or cyclosporin A. However, recent clinical evidence demonstrates promising results for biological drugs, particularly interleukin inhibitors. A systematic review and meta-analysis revealed that IL-1 inhibitors (IL-1i) and IL-6 receptor inhibitors (IL-6Ri) show the highest level of efficacy in managing Still's disease, with anakinra consistently ranked as the most effective intervention for achieving clinical responses. These biological therapies have demonstrated superior efficacy with favorable safety profiles, transforming the management approach for patients with limited treatment options.
The Still's disease pipeline contains several innovative therapies targeting novel pathways. Notable emerging treatments include Camoteskimab (CERC-007), a high-affinity, fully human anti-IL-18 monoclonal antibody being developed by Apollo Therapeutics. The first Phase Ib clinical trial of CERC-007 for AOSD commenced in May 2021, with the primary objective of determining safety, tolerability, and preliminary efficacy. Another promising candidate is Tadekinig alfa (r-hIL-18BP), a recombinant human interleukin-18 binding protein developed by AB2 Bio that inhibits the proinflammatory cytokine IL-18. Swedish Orphan Biovitrum's KINERET, an interleukin-1 receptor antagonist, is also under evaluation in a Phase III study for Still's disease treatment.
Recent clinical developments have underscored the therapeutic potential of targeting specific inflammatory pathways in Still's disease. In February 2025, the FDA granted Priority Review to Sobi's supplemental Biologics License Application for GAMIFANT for use in adults and children with hemophagocytic lymphohistiocytosis/macrophage activation syndrome associated with Still's disease, particularly in patients with inadequate response or intolerance to glucocorticoids, or with recurrent MAS. The target decision date (PDUFA) is June 27, 2025.
Discover evolving trends in the Still's disease treatment landscape @ Still's disease Recent Developments [https://www.delveinsight.com/sample-request/stills-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Despite these advances, significant challenges remain in the Still's disease treatment landscape, including diagnostic delays due to the condition's rarity and symptom overlap with other inflammatory disorders. The most severe complication, Macrophage Activation Syndrome (MAS), affects approximately 10-15% of patients and is associated with high mortality rates. This complication, along with treatment-related adverse effects and high therapy costs, represents substantial unmet needs that emerging therapies aim to address.
Looking ahead, the Still's disease market is expected to witness continued innovation focused on targeted therapies, combination approaches, and personalized treatment strategies. As research further elucidates the molecular mechanisms underlying the disease, next-generation biologics and small molecules targeting specific inflammatory pathways are likely to reshape treatment paradigms, potentially improving long-term outcomes and quality of life for patients with this challenging condition.
Table of Contents
1. Key Insights
2. Executive Summary of Still's Disease
3. Competitive Intelligence Analysis for Still's Disease
4. Still's Disease: Market Overview at a Glance
5. Still's Disease: Disease Background and Overview
6. Still's Disease Patient Journey
7. Still's Disease Epidemiology and Patient Population
8. Still's Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Still's Disease Unmet Needs
10. Key Endpoints of Still's Disease Treatment
11. Still's Disease Marketed Products
12. Still's Disease Emerging Therapies
13. Still's Disease: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Still's Disease
17. KOL Views
18. Still's Disease Market Drivers
19. Still's Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports:
Still's Disease Pipeline Insight [https://www.delveinsight.com/sample-request/stills-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Still's disease Pipeline Insight provides comprehensive insights about the Still's disease pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Still's disease companies, including Swedish Orphan Biovitrum, R-Pharm International, LLC, Syneos Health, Apollo Therapeutics Ltd, and AB2 Bio, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=stills-disease-treatment-market-poised-for-significant-growth-driven-by-therapies-targeting-novel-pathways-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Still's Disease Treatment Market Poised for Significant Growth, Driven by Therapies Targeting Novel Pathways | DelveInsight here
News-ID: 4013363 • Views: …
More Releases from ABNewswire
How to Leverage Gimbal Camera for Resource Exploration
Image: https://www.viewprouav.com/uploads/%E6%B5%8B%E7%BB%981.jpg
Gimbal Camera technology is playing an increasingly important role in resource exploration, especially in industries such as mining, oil, and natural gas. By being mounted on drones, helicopters, or other aerial platforms, Gimbal Cameras utilize their stable imaging capabilities and high-resolution image capture to provide precise real-time data support for resource exploration. Below are the main applications of Gimbal Camera in resource exploration:
1. Geological Structure and Terrain Analysis
Gimbal Camera,…
Viewpro Chinese New Year Holiday Notice
Dear Valued Customers and Partners,
As the Chinese New Year approaches, all of us at Viewpro would like to express our sincere gratitude for your continued support and trust.
Please be informed that our Chinese New Year holiday will be observed from:February 14 to February 23, 2026We will resume normal operations on February 24, 2026.
During the holiday, a limited number of staff will remain on duty to handle urgent matters. However, responses…
Hoyeah WPC: Empowering Modern Architecture - Redefining Space with Eco-Conscious …
Hoyeah WPC: Empowering Modern Architecture - Redefining Space with Eco-Conscious Durability
As global environmental standards tighten and the construction industry increasingly prioritizes sustainable materials, wood-plastic composite (WPC) has emerged as a preferred choice for outdoor landscapes, interior decoration, and public building projects - thanks to its dual advantages of resource efficiency and reliable performance. As a specialized WPC solutions provider, Hoyeah [https://www.hoyeahchina.com/]WPC [https://www.hoyeahchina.com/] leverages mature technological expertise to integrate the core…
Monk Fruit Extract: Why Is It Becoming a Strategic Natural Sweetener for Global …
As global sugar reduction policies tighten and consumer awareness of metabolic health increases, Monk Fruit Extract has rapidly emerged as one of the most promising natural high-intensity sweeteners in the international market. Derived from Siraitia grosvenorii, monk fruit extract offers sweetness without calories, making it highly attractive to food, beverage, and nutraceutical manufacturers worldwide.
With increasing regulatory acceptance and clean-label demand, global buyers are actively seeking reliable monk fruit extract suppliers.…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
